Drugs / NNC0268-0965
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04575181 | Oct 2020 → Dec 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04136067 | Oct 2019 → Aug 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03965013 | Jun → Dec 2019 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0268-0965 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04575181 ↗ |
| Known as | insulin 965 | “This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood...” NCT03965013 ↗2“This study looks at the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965)” NCT04136067 ↗ “The study will look at the efficacy and safety of NNC0268-0965 (referred to as insulin 965).” NCT04575181 ↗ |
| Modality | Protein / enzyme biologic | “Participants will get either the new insulin 965 or insulin glargine - a medicine that doctors already can prescribe (Lantus®).” NCT04575181 ↗ |
| Route | Subcutaneous | “A single dose of NNC0268-0965 given s.c. (subcutaneously, under the skin)” NCT03965013 ↗ |